Evidence map›Paper›PMID 36275624›Full record

ArticleFrontiers in molecular biosciences2022

A non-traditional crystal-based compound screening method targeting the ATP binding site of

Alexander Mrozek, Tetyana Antoshchenko, Yun Chen, Carlos Zepeda-Velázquez, David Smil, Nirbhay Kumar, Hua Lu, Hee-Won Park

Open access · goldAbstract read
In one paragraph

Article in Frontiers in molecular biosciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Frontiers in molecular biosciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Alexander MrozekDepartment of Biochemistry & Molecular Biology, Tulane University School of Medicine, New Orleans, LA, United States.
Tetyana AntoshchenkoDepartment of Biochemistry & Molecular Biology, Tulane University School of Medicine, New Orleans, LA, United States.
Yun ChenDepartment of Biochemistry & Molecular Biology, Tulane University School of Medicine, New Orleans, LA, United States.
Carlos Zepeda-VelázquezDrug Discovery Program, Ontario Institute for Cancer Research, Toronto, ON, Canada.
David SmilDrug Discovery Program, Ontario Institute for Cancer Research, Toronto, ON, Canada.
Nirbhay KumarDepartment of Global Health, George Washington University Milken Institute of Public Health, Washington, D.C., DC, United States.
Hua LuDepartment of Biochemistry & Molecular Biology, Tulane University School of Medicine, New Orleans, LA, United States.
Hee-Won ParkDepartment of Biochemistry & Molecular Biology, Tulane University School of Medicine, New Orleans, LA, United States.
Tulane University · USOntario Institute for Cancer Research · CAGeorge Washington University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug resistance to front-line malarial treatments represents an ongoing threat to control malaria, a vector borne infectious disease. The malarial parasite,

Indexed as

chaperonedrug discovery & developmentGRP78malarianucleoside analoguesPlasmodium falciparumunfolded protein response

Identifiers

PMID36275624
PMCPMC9585173
OpenAlexW4303021556

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.